Daniel Costa

Dr. Daniel Costa

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in RadioGraphics
Verified
Journal Article
Closed access
DCDaniel Costa
Daniel Costa
IPIvan Pedrosa
Ivan Pedrosa
FDFrancisco Donato
Francisco Donato
CRClaus G. Roehrborn
Claus G. Roehrborn
NRNeil M. Rofsky
Neil M. Rofsky
MR imaging–transrectal US fusion biopsy improves detection of clinically significant prostate cancer and may allow more reliable risk stratification in patients with known cancer. Cancer of the prostate gland is a common but heterogeneous disease requiring individualized risk stratification for optimal clinical management. However, transrectal ultrasonography (US)–guided biopsy—the standard of care for diagnosis of prostate cancer—frequently fails to detect aggressive tumors or provide reliable parameters for pretreatment risk stratification. Multiparametric magnetic resonance (MR) imaging is the most accurate imaging technique for prostate cancer detection and local staging. Recently, different approaches have been developed to allow targeted biopsies of areas that are suspicious for cancer at MR imaging, including direct MR imaging guidance and MR imaging–transrectal US fusion, which can be achieved with cognitive fusion or software assistance. Regardless of the technique used, targeted prostate biopsies have the potential to increase detection of clinically relevant prostate cancer and provide more reliable risk stratification in patients with known cancer. The authors discuss t...

1 July 2019 in European Urology Oncology
Verified
Journal Article
Closed access
DCDaniel Costa
Daniel Costa
KGKenneth Goldberg
Kenneth Goldberg
ALAlberto Diaz de Leon
Alberto Diaz de Leon
YLYair Lotan
Yair Lotan
YXYin Xi
Yin Xi
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu

1 June 2014 in Academic Radiology
Verified
Journal Article
Closed access
FDFrancisco Donato
Francisco Donato
DCDaniel Costa
Daniel Costa
QYQing Yuan
Qing Yuan
NRNeil M. Rofsky
Neil M. Rofsky
RLRobert E. Lenkinski
Robert E. Lenkinski
IPIvan Pedrosa
Ivan Pedrosa

1 January 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
YFYuval Freifeld
Yuval Freifeld
YXYin Xi
Yin Xi
NPNiccolo Passoni
Niccolo Passoni
SWSolomon Woldu
Solomon Woldu
BHBrad Hornberger
Brad Hornberger
DCDaniel Costa
Daniel Costa

1 June 2016 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
DCDaniel Costa
Daniel Costa
QYQing Yuan
Qing Yuan
YXYin Xi
Yin Xi
NRNeil M. Rofsky
Neil M. Rofsky
RLRobert E. Lenkinski
Robert E. Lenkinski
IPIvan Pedrosa
Ivan Pedrosa

1 January 2016 in Journal of Urology
Verified
Journal Article
Closed access
DCDaniel Costa
Daniel Costa
YLYair Lotan
Yair Lotan
NRNeil M. Rofsky
Neil M. Rofsky
CRClaus Roehrborn
Claus Roehrborn
ALAlexander Liu
Alexander Liu
IPIvan Pedrosa
Ivan Pedrosa
We assess the performance of prospectively assigned magnetic resonance imaging based Likert scale scores for the detection of clinically significant prostate cancer, and analyze the pre-biopsy imaging variables associated with increased cancer detection using targeted magnetic resonance imaging-transrectal ultrasound fusion biopsy. In this retrospective review of prospectively generated data including men with abnormal multiparametric prostate magnetic resonance imaging (at least 1 Likert score 3 or greater lesion) who underwent subsequent targeted magnetic resonance imaging-transrectal ultrasound fusion biopsy, we determined the association between different imaging variables (Likert score, lesion size, lesion location, prostate volume, radiologist experience) and targeted biopsy positivity rate. We also compared the detection of clinically significant cancer according to Likert scale scores. Tumors with high volume (50% or more of any core) Gleason score 3+4 or any tumor with greater Gleason score were considered clinically significant. Each lesion served as the elementary unit for analysis. We used logistic regression for univariate and multivariate (stepwise selection) analysis to assess for an association between targeted biopsy positivity rate and each tested variable. The relationship between Likert scale and Gleason score was evaluated using the Spearman correlation coefficient. A total of 161 men with 244 lesions met the study eligibility criteria. Targeted biopsies diagnosed cancer in 41% (66 of 161) of the men and 41% (99 of 244) of the lesions. The Likert score was the strongest predictor of targeted biopsy positivity (OR 3.7, p <0.0001). Other imaging findings associated with a higher targeted biopsy positivity rate included smaller prostate volume (OR 0.7, p <0.01), larger lesion size (OR 2.2, p <0.001) and anterior location (OR 2.0, p=0.01). On multiple logistic regression analysis Likert score, lesion size and prostate volume were significant predictors of targeted biopsy positivity. Higher Likert scores were also associated with increased detection of clinically significant tumors (p <0.0001). The Likert scale score used to convey the degree of suspicion on multiparametric magnetic resonance imaging is the strongest predictor of targeted biopsy positivity and of the presence of clinically significant tumor.